Capricor Therapeutics' (CAPR) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR - Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $8.00 target price on the biotechnology company's stock.

CAPR has been the topic of a number of other reports. HC Wainwright reiterated a buy rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday. StockNews.com upgraded shares of Capricor Therapeutics from a sell rating to a hold rating in a report on Wednesday, January 24th.

Capricor Therapeutics Stock Down 4.4 %

NASDAQ:CAPR traded down $0.24 during midday trading on Tuesday, reaching $5.20. The stock had a trading volume of 667,272 shares, compared to its average volume of 298,965. The stock has a market cap of $163.80 million, a P/E ratio of -5.98 and a beta of 4.06. The firm has a fifty day simple moving average of $5.93 and a two-hundred day simple moving average of $4.59. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $8.22.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.21. The business had revenue of $12.09 million for the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. On average, sell-side analysts anticipate that Capricor Therapeutics will post -0.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $40,000. Jump Financial LLC bought a new position in Capricor Therapeutics in the fourth quarter worth about $258,000. Citigroup Inc. acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $211,000. Finally, Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.